CAMK1D and central nervous system cancer: The survival analysis indicated that glioma patients with lower expression of CAMK1D in TCGA (HR: 0.33, 95% CI 0.25–0.44), CGGA (HR: 0.60, 95% CI 0.51–0.71), Rembrandt (HR: 0.54, 95% CI 0.43–0.68), Gravendeel (HR: 0.56, 95% CI 0.43–0.73), Kamoun (HR: 0.81, 95% CI 0.44–1.49), Phillips (HR: 0.43, 95% CI 0.26–0.73), Freije (HR: 1.04, 95% CI 0.62–1.73), and LeeY (HR: 0.85, 95% CI 0.63–1.14) exhibited significantly shorter survival time than patients with higher expression, while patients from the Kamoun cohort displayed the same trend with no statistical significance (Figure 2A).